Biotech Values

[DewDiligence]

More on Epirus Biopharma’s business plan (from FierceBiotech):

http://www.fiercebiotech.com/story/low-profile-epirus-lays-claim-phiii-success-remicade-biosimilar/2013-08-29

[CEO] Munshi has come up with a new strategy for biosimilar development work. Rather than focus primarily on the U.S. and Europe, two huge markets attracting the attention of multinational players, he's zeroed in on emerging markets like South Africa and Brazil. By partnering with manufacturers already on the ground…the company can improve its chances of pushing ahead with local regulators while gaining government support to build facilities and winning government contracts for lower-priced therapies.

Somebody is going to make good money doing this, so it might as well be Epirus.